KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Supernus Pharmaceuticals (SUPN) Leases (2019 - 2026)

Supernus Pharmaceuticals has reported Leases over the past 7 years, most recently at $26.7 million for Q4 2025.

  • Quarterly Leases rose 9.13% to $26.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.7 million through Dec 2025, up 9.13% year-over-year, with the annual reading at $26.7 million for FY2025, 9.13% up from the prior year.
  • Leases was $26.7 million for Q4 2025 at Supernus Pharmaceuticals, down from $28.8 million in the prior quarter.
  • Over five years, Leases peaked at $35.4 million in Q4 2021 and troughed at $20.1 million in Q1 2021.
  • The 5-year median for Leases is $29.0 million (2023), against an average of $28.3 million.
  • The largest YoY upside for Leases was 60.14% in 2022 against a maximum downside of 18.27% in 2022.
  • A 5-year view of Leases shows it stood at $35.4 million in 2021, then decreased by 18.27% to $28.9 million in 2022, then grew by 0.31% to $29.0 million in 2023, then fell by 15.58% to $24.5 million in 2024, then increased by 9.13% to $26.7 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Leases are $26.7 million (Q4 2025), $28.8 million (Q3 2025), and $21.9 million (Q2 2025).